Revolution Medicines (RVMD) Receivables (2020 - 2023)

Revolution Medicines' Receivables history runs 4 years deep, the most recent figure standing at $1.3 million for Q4 2023.

• In Q4 2023, Receivables fell 73.16% year-over-year to $1.3 million; the TTM figure through Dec 2023 stood at $1.3 million (down 73.16% YoY), while the FY2023 annual figure was $1.3 million, down 73.16% from the prior year.
• Receivables for Q4 2023 stood at $1.3 million, up from $309000.0 in the prior quarter.
• The five-year high for Receivables was $12.8 million in Q4 2020, with the low at $309000.0 in Q3 2023.
• The 4-year median for Receivables is $5.4 million (2022), against an average of $5.3 million.
• The sharpest annual moves came in 2022 and 2023: Receivables decreased 13.83% in 2022, then tumbled 93.74% in 2023.
• Revolution Medicines' Receivables stood at $12.8 million in 2020, then tumbled by 53.63% to $5.9 million in 2021, then slipped by 21.18% to $4.7 million in 2022, then sank by 73.16% to $1.3 million in 2023.
• Business Quant data shows RVMD's Receivables at $1.3 million in Q4 2023, $309000.0 in Q3 2023, and $2.5 million in Q2 2023.